Encapsulated cell therapy - Alzheimers's disease - NsGene

Drug Profile

Encapsulated cell therapy - Alzheimers's disease - NsGene

Alternative Names: ECB-AD; ECT-AD; ECT-NGF; NsG0202

Latest Information Update: 11 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NsGene
  • Class Cell therapies; Gene therapies; Nerve growth factors
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 11 May 2016 Phase I development is ongoing in Sweden
  • 19 Nov 2008 Pharmacodynamics data from a preclinical study in Alzheimer's disease presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 10 Apr 2008 NsGene is seeking licensing or partnering opportunities for NsG 0202 (http://www.nsgene.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top